Type 2 Diabetes – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Type 2 Diabetes – Pipeline Review, H2 2020’, provides an overview of the Type 2 Diabetes pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Type 2 Diabetes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes

– The report reviews pipeline therapeutics for Type 2 Diabetes by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Type 2 Diabetes therapeutics and enlists all their major and minor projects

– The report assesses Type 2 Diabetes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Type 2 Diabetes

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

Adare Pharma Solutions

ADM Therapeutics

Adocia SAS

Aerami Therapeutics

Afimmune Biopharma Ltd

AgeX Therapeutics Inc

Akero Therapeutics Inc

Akston Biosciences Corp

Algiax Pharmaceuticals GmbH

Alms Therapeutics

AlphaMab Co Ltd

Amgen Inc

AmideBio LLC

Anagenesis Biotechnologies SAS

Anji Pharmaceuticals Inc

AnyGen Co Ltd

Apcegen Technologies Pvt Ltd

Aphios Corp

Apoglyx AB

APT Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Type 2 Diabetes- Overview

Type 2 Diabetes- Therapeutics Development

Type 2 Diabetes- Therapeutics Assessment

Type 2 Diabetes- Companies Involved in Therapeutics Development

Type 2 Diabetes- Drug Profiles

Type 2 Diabetes- Dormant Projects

Type 2 Diabetes- Discontinued Products

Type 2 Diabetes- Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Type 2 Diabetes, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Type 2 Diabetes – Pipeline by 3SBio Inc, H2 2020

Type 2 Diabetes – Pipeline by Adare Pharma Solutions, H2 2020

Type 2 Diabetes – Pipeline by ADM Therapeutics, H2 2020

Type 2 Diabetes – Pipeline by Adocia SAS, H2 2020

Type 2 Diabetes – Pipeline by Aerami Therapeutics, H2 2020

Type 2 Diabetes – Pipeline by Afimmune Biopharma Ltd, H2 2020

Type 2 Diabetes – Pipeline by AgeX Therapeutics Inc, H2 2020

Type 2 Diabetes – Pipeline by Akero Therapeutics Inc, H2 2020

Type 2 Diabetes – Pipeline by Akston Biosciences Corp, H2 2020

Type 2 Diabetes – Pipeline by Algiax Pharmaceuticals GmbH, H2 2020

Type 2 Diabetes – Pipeline by Alms Therapeutics, H2 2020

Type 2 Diabetes – Pipeline by AlphaMab Co Ltd, H2 2020

Type 2 Diabetes – Pipeline by Amgen Inc, H2 2020

Type 2 Diabetes – Pipeline by AmideBio LLC, H2 2020

Type 2 Diabetes – Pipeline by Anagenesis Biotechnologies SAS, H2 2020

Type 2 Diabetes – Pipeline by Anji Pharmaceuticals Inc, H2 2020

Type 2 Diabetes – Pipeline by AnyGen Co Ltd, H2 2020

Type 2 Diabetes – Pipeline by Apcegen Technologies Pvt Ltd, H2 2020

Type 2 Diabetes – Pipeline by Aphios Corp, H2 2020

Type 2 Diabetes – Pipeline by Apoglyx AB, H2 2020

Type 2 Diabetes – Pipeline by APT Therapeutics Inc, H2 2020

Type 2 Diabetes – Pipeline by Aptamer Sciences Inc, H2 2020

Type 2 Diabetes – Pipeline by AptamiR Therapeutics Inc, H2 2020

Type 2 Diabetes – Pipeline by Ariddad Therapeutics SL, H2 2020

Type 2 Diabetes – Pipeline by Arkay Therapeutics LLC, H2 2020

Type 2 Diabetes – Pipeline by Artery Therapeutics Inc, H2 2020

Type 2 Diabetes – Pipeline by AsiaBiome, H2 2020

Type 2 Diabetes – Pipeline by Astellas Pharma Inc, H2 2020

Type 2 Diabetes – Pipeline by AstraZeneca Plc, H2 2020

Type 2 Diabetes – Pipeline by Atrogi AB, H2 2020

Type 2 Diabetes – Pipeline by Auritec Pharmaceuticals Inc, H2 2020

Type 2 Diabetes – Pipeline by Avolynt Inc, H2 2020

Type 2 Diabetes – Pipeline by Beijing Eastern Biotech Co Ltd, H2 2020

Type 2 Diabetes – Pipeline by Beijing SL Pharmaceutical Co Ltd, H2 2020

Type 2 Diabetes – Pipeline by Betagenon AB, H2 2020

Type 2 Diabetes – Pipeline by Betta Pharmaceuticals Co Ltd, H2 2020

Type 2 Diabetes – Pipeline by Biocon Ltd, H2 2020

Type 2 Diabetes – Pipeline by BioEos Ltd, H2 2020

Type 2 Diabetes – Pipeline by Biogenomics Ltd, H2 2020

Type 2 Diabetes – Pipeline by BioKier Inc, H2 2020

Type 2 Diabetes – Pipeline by BioLingus AG, H2 2020

Type 2 Diabetes – Pipeline by BioRestorative Therapies Inc, H2 2020

Type 2 Diabetes – Pipeline by Biozeus Pharmaceutical SA, H2 2020

Type 2 Diabetes – Pipeline by Boehringer Ingelheim International GmbH, H2 2020

Type 2 Diabetes – Pipeline by Bopin (Shanghai) Biomedical Technology Co Ltd, H2 2020

Type 2 Diabetes – Pipeline by Boryung Pharmaceutical Co Ltd, H2 2020

Type 2 Diabetes – Pipeline by Boston Therapeutics Inc, H2 2020

Type 2 Diabetes – Pipeline by Braasch Biotech LLC, H2 2020

Type 2 Diabetes – Pipeline by BrightGene Bio-Medical Technology Co Ltd, H2 2020

Type 2 Diabetes – Pipeline by Buto Biopharma Inc, H2 2020

Type 2 Diabetes – Pipeline by C4X Discovery Holdings Plc, H2 2020

Type 2 Diabetes – Pipeline by Cadila Healthcare Ltd, H2 2020

Type 2 Diabetes – Pipeline by Cadila Pharmaceuticals Ltd, H2 2020

Type 2 Diabetes – Pipeline by Caelus Health, H2 2020

Type 2 Diabetes – Pipeline by Caldan Therapeutics Ltd, H2 2020

Type 2 Diabetes – Pipeline by CAR-T (Shanghai) Biotechnology Co Ltd, H2 2020

Type 2 Diabetes – Pipeline by Carlina Technologies SAS, H2 2020

Type 2 Diabetes – Pipeline by Carmot Therapeutics Inc, H2 2020

Type 2 Diabetes – Pipeline by Cellix Bio Pvt Ltd, H2 2020

Type 2 Diabetes – Pipeline by Celon Pharma SA, H2 2020

Type 2 Diabetes – Pipeline by Centaurus Therapeutics Inc, H2 2020

Type 2 Diabetes – Pipeline by Vivus Inc, H2 2020

Type 2 Diabetes – Pipeline by vTv Therapeutics Inc, H2 2020

Type 2 Diabetes – Pipeline by Vybion Inc, H2 2020

Type 2 Diabetes – Pipeline by Wuxi Hebang Biotechnology Co Ltd, H2 2020

Type 2 Diabetes – Pipeline by XERIS Pharmaceuticals Inc, H2 2020

Type 2 Diabetes – Pipeline by XL-protein GmbH, H2 2020

Type 2 Diabetes – Pipeline by XOMA Corp, H2 2020

Type 2 Diabetes – Pipeline by XuanZhu Pharma Co Ltd, H2 2020

Type 2 Diabetes – Pipeline by Yichang Hec Changjiang Pharmaceutical Co Ltd, H2 2020

Type 2 Diabetes – Pipeline by Youngene Therapeutics Co Ltd, H2 2020

Type 2 Diabetes – Pipeline by Zealand Pharma AS, H2 2020

Type 2 Diabetes – Pipeline by Zhejiang Doer Biologics Corp, H2 2020

Type 2 Diabetes – Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2020

Type 2 Diabetes – Pipeline by Zhejiang Huayang Pharmaceutical Co Ltd, H2 2020

Type 2 Diabetes – Pipeline by Zih Yuan Tang Biotechnology Co Ltd, H2 2020

Type 2 Diabetes – Pipeline by Zucara Therapeutics Inc, H2 2020

Type 2 Diabetes – Dormant Projects, H2 2020

Type 2 Diabetes – Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development for Type 2 Diabetes, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports